ClinicaliQ Trial Snapshot
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) — Recruiting • Phase III • Oncology • NCT07286266.
- What is being tested: Mocertatug rezetecan (Mo-Rez), a novel targeted therapy, is being compared against standard-of-care treatment in patients with platinum-resistant ovarian cancer, with evaluation of efficacy, safety, and tolerability.
- Patient eligibility overview: The trial enrolls patients with platinum-resistant ovarian cancer (those who have relapsed within 6 months of platinum-based chemotherapy or are refractory to platinum agents), representing a treatment-resistant population with limited therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Eligibility Snapshot
- : * Is at least 18 years of age and the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the Informed Consent Form (ICF). * Has epithelial ovarian cancer, inclusive of primary peritoneal or fallopian-tube cancer with a histologically confirmed diagnosis of high grade serous, high grade endometrioid, or clear cell carcinoma, or carcinosarcoma that is resistant to platinum-based therapy. Platinum-resistance is defined as follows: * Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of platinum therapy, must have had a response (CR, PR, stable disease) and then progressed from >3 months to ≤6 months after the last dose of platinum therapy. * Participants who have received >1 line of platinum therapy must have progressed on or ≤6 months after the date of the last dose of platinum therapy. • Has received at least 1 but no more than 4 prior lines of systemic anti-cancer therapy. Prior lines of therapy are defined as follows: * Adjuvant ± neoadjuvant are considered one line of therapy. * Maintenance therapy (e.g., bevacizumab, [poly adenosine diphosphate-ribosylation (ADP) ribose polymerase inhibitor (PARPi)] will be…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.